Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis.

Kandola, L; Swannell, A J; Hunter, Ann

doi:10.1136/ard.54.6.529-b

Cited by 11 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chloramphenicol, rarely used at present, causes a reversible suppression of erythropoiesis and produces ringed sideroblasts [ 17 ]. Linezolide, penicillamine, and triethylene tetramine dihydrochloride (a chelating agent used to treat Wilson's disease) induce reversible SA [ 19 – 21 ]. Myelodysplasias and secondary acute leukemias induced by chemotherapy, discussed below, may initially manifest as sideroblastic anemia [ 22 ].…”

Section: Sideroblastic Anemiamentioning

confidence: 99%

Drug-Induced Hematologic Syndromes

Mintzer

Billet

Chmielewski

2009

Advances in Hematology

View full text Add to dashboard Cite

Objective. Drugs can induce almost the entire spectrum of hematologic disorders, affecting white cells, red cells, platelets, and the coagulation system. This paper aims to emphasize the broad range of drug-induced hematological syndromes and to highlight some of the newer drugs and syndromes. Methods. Medline literature on drug-induced hematologic syndromes was reviewed. Most reports and reviews focus on individual drugs or cytopenias. Results. Drug-induced syndromes include hemolytic anemias, methemoglobinemia, red cell aplasia, sideroblastic anemia, megaloblastic anemia, polycythemia, aplastic anemia, leukocytosis, neutropenia, eosinophilia, immune thrombocytopenia, microangiopathic syndromes, hypercoagulability, hypoprothrombinemia, circulating anticoagulants, myelodysplasia, and acute leukemia. Some of the classic drugs known to cause hematologic abnormalities have been replaced by newer drugs, including biologics, accompanied by their own syndromes and unintended side effects. Conclusions. Drugs can induce toxicities spanning many hematologic syndromes, mediated by a variety of mechanisms. Physicians need to be alert to the potential for iatrogenic drug-induced hematologic complications.

show abstract